about
The endocannabinoid system, cannabinoids, and painThe endocannabinoid system as an emerging target of pharmacotherapyHemopressin is an inverse agonist of CB1 cannabinoid receptorsThe endocannabinoid system as a potential therapeutic target for pain modulationIdentification of a high-affinity binding site involved in the transport of endocannabinoids.Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous systemMonoglyceride lipase deficiency affects hepatic cholesterol metabolism and lipid-dependent gut transit in ApoE-/- mice.The role of endocannabinoids in pain modulation.Cannabinoids inhibit acid-sensing ion channel currents in rat dorsal root ganglion neurons.Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells.The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.The therapeutic potential of cannabis in multiple sclerosis.Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.Cannabinoid modulation of neuroinflammatory disorders.Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?Experience with the synthetic cannabinoid nabilone in chronic noncancer pain.Targeted lipidomics: discovery of new fatty acyl amidesBrain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer painCritical appraisal of the potential use of cannabinoids in cancer management.The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanismsSingle and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis usersDynamic regulation of the endocannabinoid system: implications for analgesia.Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example.Dynamic changes to the endocannabinoid system in models of chronic pain.Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.Cannabinoids for neuropathic pain.Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….The cannabinoid system and pain.Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic ratsCannabinoids in the management of difficult to treat painPotentiation by WIN 55,212-2 of GABA-activated currents in rat trigeminal ganglion neurones.Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.
P2860
Q24601890-F6FAB0B8-EDDC-4C09-B632-C016273EE87FQ24648473-C01FF13E-BB4D-43E9-9BA6-97AD4E41AC7CQ24683759-59067D4F-538C-45D2-9D7D-90845D5C7940Q28247621-6DD5BE63-FE1F-4943-AEBB-76777D6E4D2EQ28284073-F8E77653-46C8-4ABE-AC52-610678D38DDEQ28575053-0EE3972F-BD57-4FFB-B68A-D1DE3644BEE8Q33779386-8DA736B1-A2A4-44C9-A54D-CEBB8AC4EE94Q34320270-35F5F39D-5EF1-4AD8-9C06-2350688BA9EAQ34429295-3A6549AF-596C-4C5C-81E3-78E05A766719Q34490167-3CADBF93-2866-4606-9704-99D032ECC57AQ34634096-FD7C5E45-9868-4AFF-9F61-E3182996B7FAQ34659000-0FD05AAE-AF36-4B57-9370-5B34B9906D5CQ35094657-516AFF4B-D951-449E-B2FD-04EE404E6FF2Q35138445-D3B97036-3584-4E4D-BEA8-C0C2A16494DBQ36015427-7AFE9E17-E447-4247-B00B-54D3EC955F8BQ36067324-3F6F363E-C33E-4472-9F97-78807EAAB29CQ36157657-0D09B46E-0CDF-4155-922D-BFD5CD2BDDA7Q36419669-C4E30B28-504B-41BD-9921-A18DE2EDA8A4Q36616306-E93AC937-3B9A-4B69-978E-63509F7D02A3Q36799066-A8392C3A-B2DD-4AD3-B03D-BAC25D919370Q36912778-70EF9E95-B0A3-4DBB-8CD3-947A111CCDD0Q36978586-6DD432D3-04FF-4F70-B620-4B542E7F62E9Q37120771-0F5ECA35-ED35-49D8-BD61-5ADA6975F598Q37164208-9276325E-E162-4542-ABAB-50D2EB50E911Q37182268-FD49288C-E578-48A3-AB93-173E076178F7Q37210189-50007319-FF62-4562-BE1F-B416858D03CAQ37611106-7316FCF0-1FAC-4992-AD88-C702B4050C68Q37872360-F2FEADCB-4141-4C9E-A12C-238389177200Q38056398-574CD762-1053-48F5-9499-01C3932DFB7AQ38102053-05886BDC-1D9E-4303-A353-FBB5498C5255Q38243708-4C4278E5-18B6-4164-BB88-A6D8A7218BF1Q38287745-B64C1426-11E7-4E79-94E6-9B48F9B36564Q38503842-53C70D31-EA4D-4A99-92D4-66BA508DB286Q38669685-527BEF92-220A-411B-89C1-8B24DA35C00FQ39192669-73D87136-FEEC-4FC0-8273-682C7164D9F7Q39650051-3AA044E3-0F9E-4B15-8F5E-BB85B70C64D0Q39697570-D10FF164-9877-4B97-A6B6-B247369AB4AAQ41687142-308C8881-0544-40BF-82F9-7409F0DDBE26Q41868283-9D3114EC-51C9-4B28-AEF7-C6BEC10C81F5Q41958365-6465CEE7-BB6D-49AA-8C3E-0B13E5BA2EDC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cannabinoid analgesia.
@ast
Cannabinoid analgesia.
@en
Cannabinoid analgesia.
@nl
type
label
Cannabinoid analgesia.
@ast
Cannabinoid analgesia.
@en
Cannabinoid analgesia.
@nl
prefLabel
Cannabinoid analgesia.
@ast
Cannabinoid analgesia.
@en
Cannabinoid analgesia.
@nl
P1476
Cannabinoid analgesia.
@en
P2093
J Michael Walker
Susan M Huang
P304
P356
10.1016/S0163-7258(02)00252-8
P577
2002-08-01T00:00:00Z